Table 2.
Ongoing clinical trials of new drugs for refractory ITP.
|
Intervention
/Treatment |
Mechanism | Phase |
Condition/
Disease |
Route of administration | Identifier |
| SKI-O-703 | Syk inh | 2 | Persistent and chronic ITP | Oral | NCT04056195 |
| HMPL-523 | Syk inh | 1 | ITP | Oral | NCT03951623 |
| Orelabrutinib | BTK inh | 2 | Refractory ITP | Oral | NCT05020288 |
| Rilzabrutinib (PRN1008) | BTK inh | 3 | Persistent or chronic ITP | Oral | NCT04562766 |
| Bortezomib | Proteasome inh | 2 | ITP | IV | NCT03013114 |
| Bortezomib+R vs. RTX |
Proteasome inh Anti-CD20 |
3 | Newly diagnosed ITP | SC vs. IV |
NCT03443570 |
| Decitabine | Demethylation | 3 | Newly diagnosed ITP | IVGTT | NCT03252457 |
| Oseltamivir | Sialidase inh | 3 | ITP | Oral | NCT03520049 |
| Efgartigimod | FcRn-targeting therapeutic | 3 | ITP | IV |
NCT04188379 NCT04225156 |
| Efgartigimod | FcRn-targeting therapeutic | 3 | ITP | SC |
NCT04812925 NCT04687072 |
| Rozanolixizumab | FcRn-targeting therapeutic | 3 | Persistent or chronic ITP | SC |
NCT04596995 NCT04224688 NCT04200456 |
| HBM9161 | FcRn-targeting therapeutic | 2/3 | ITP | IV | NCT04428255 |
| GL-2045 | FcR–targeting biologics | 1 | ITP | SC IV |
NCT03275740 |
| Atorvastatin | Improve endothelial function | 2/3 | Newly diagnosed ITP | Oral | NCT03692754 |
| Chidamide | Histone deacetylase inh | 2 | Refractory ITP | Oral | NCT03838354 |
| UC-MSCs | Improving immune tolerance | N/A | Refractory ITP | – | NCT04014166 |
inh, inhibitor; IV, intravenous injection; RTX, rituximab; SC, subcutaneous injection; IVGTT, intravenously guttae; UC-MSCs, human umbilical cord-derived mesenchymal stem cells; N/A, not available.